Tumor cell membrane phospholipids and mitochondria

Tumor cell membrane phospholipids and mitochondria represent a dual-compartment therapeutic target utilized by membrane-active anticancer agents [1]. This target profile is characterized by the distinct biophysical properties of malignant cells, such as the loss of phospholipid asymmetry leading to increased surface exposure of anionic lipids like phosphatidylserine and the presence of altered lipid rafts [2, 3]. Drugs targeting these components, such as alkylphosphocholines (e.g., edelfosine), initially integrate into the plasma membrane to disrupt survival signaling pathways before translocating to the mitochondria [2]. Once at the mitochondria, these agents induce membrane permeabilization and the release of pro-apoptotic factors like cytochrome c, effectively triggering cell death [1, 4]. This approach is particularly valuable for overcoming multi-drug resistance that often arises from mutations in specific protein receptors or enzymes [2]. Furthermore, the targeting of mitochondrial membranes allows for the direct activation of the intrinsic apoptotic pathway, bypassing upstream signaling blocks common in many cancers [1]. The specificity of these agents often relies on the higher negative charge and increased fluidity of tumor cell membranes compared to healthy cells [3].

Other names

Tumor cell membranesMitochondrial membranesAnionic phospholipidsLipid raftsMitochondrial outer membrane

Induction of apoptosis through the disruption of cell membrane lipid rafts and subsequent permeabilization of the mitochondrial outer membrane (MOMP) [1, 2].